- Home
- CPRI vs GH Comparison
CPRI vs GH Comparison
Compare CPRI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- GH
- Stock Information
- Founded
- CPRI 1981
- GH 2011
- Country
- CPRI United Kingdom
- GH United States
- Employees
- CPRI N/A
- GH N/A
- Industry
- CPRI Apparel
- GH Medical Specialities
- Sector
- CPRI Consumer Discretionary
- GH Health Care
- Exchange
- CPRI Nasdaq
- GH Nasdaq
- Market Cap
- CPRI 3.9B
- GH 3.0B
- IPO Year
- CPRI 2011
- GH 2018
- Fundamental
- Price
- CPRI $38.70
- GH $26.25
- Analyst Decision
- CPRI Hold
- GH Strong Buy
- Analyst Count
- CPRI 5
- GH 17
- Target Price
- CPRI $40.40
- GH $39.31
- AVG Volume (30 Days)
- CPRI 1.7M
- GH 2.4M
- Earning Date
- CPRI 11-07-2024
- GH 11-04-2024
- Dividend Yield
- CPRI N/A
- GH N/A
- EPS Growth
- CPRI N/A
- GH N/A
- EPS
- CPRI N/A
- GH N/A
- Revenue
- CPRI $5,008,000,000.00
- GH $643,810,000.00
- Revenue This Year
- CPRI N/A
- GH $27.01
- Revenue Next Year
- CPRI $2.21
- GH $18.30
- P/E Ratio
- CPRI N/A
- GH N/A
- Revenue Growth
- CPRI N/A
- GH 26.20
- 52 Week Low
- CPRI $29.28
- GH $15.81
- 52 Week High
- CPRI $52.88
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- CPRI 65.46
- GH 47.12
- Support Level
- CPRI $34.31
- GH $24.55
- Resistance Level
- CPRI $40.70
- GH $25.87
- Average True Range (ATR)
- CPRI 1.23
- GH 1.13
- MACD
- CPRI 0.40
- GH 0.18
- Stochastic Oscillator
- CPRI 70.19
- GH 69.88
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.